Zoletero 4

Zoletero 4

zoledronic acid


Hetero Labs


Concise Prescribing Info
Zoledronic acid
Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone or tumour-induced hypercalcaemia) in adult w/ advanced malignancies involving bone. Tumour-induced hypercalcaemia.
Dosage/Direction for Use
IV infusion 4 mg every 3-4 wk. Patient w/ bone metastases w/ mild to moderate renal impairment CrCl >60 mL/min 4 mg; 50-60 mL/min 3.5 mg; 40-49 mL/min 3.3 mg; 30-39 mL/min 3 mg.
Special Precautions
Renal & hepatic insufficiency; osteonecrosis of the jaw; musculoskeletal pain, atypical fractures of the femur. Childn 1-17 yr.
Adverse Reactions
Hypophosphataemia. Anaemia; headache; conjunctivitis; nausea, vomiting, anorexia; bone pain, myalgia, arthralgia, generalised pain; renal impairment; fever, flu-like syndrome; increased blood creatinine & blood urea, hypocalcaemia.
Drug Interactions
Additive effect w/ aminoglycosides. Hypomagnesaemia w/ other potentially nephrotoxic medicinal products. Increased renal dysfunction w/ thalidomide. Osteonecrosis of the jaw w/ anti-angiogenics.
ATC Classification
M05BA08 - zoledronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Zoletero 4 soln for infusion 4 mg/5 mL
5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in